Worldwide Clinical Trials的动态

Fat's Loss of Plasticity, Not Just Excess, Fuels Obesity-Linked Diseases A review in Cell explains that obesity-related health issues, like hypertension and diabetes, result from fat's loss of plasticity—its ability to adapt to body cues—rather than just excess fat. This decline in adaptability leads to insulin resistance, inflammation, and fat cell death. Researchers suggest targeting fat tissue phenotypes for therapeutic advancements, offering new insights into treating obesity's harmful effects. #ObesityResearch #FatPlasticity #MetabolicHealth #InsulinResistance #CellJournal Credits: Cell Journalist

?? Tirzepatide improves hepatic transaminases and fat content. ?? Its effect on the parameters of hepatic fibrosis has not been proven and is inconsistent. ?? The drug has reasonable hepatic safety, with a safety profile comparable to other treatment options and placebo. Our meta-analysis has been published in Diabetes, Obesity and Metabolism, a prestigious journal with 2023 Journal Impact Factor (Clarivate) 5.4 https://lnkd.in/gJmEVwKz

further solidifying ICON plc's leading position in obesity and metabolic disease research, this whitepaper explores the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment and trials for obesity.? Definitely worth a read! #obesity #CRO #metabolichealth

At our latest event, Courtney Younglove, M.D., FOMA, FACOG, DABOM took us on a journey through her experience in obesity medicine, emphasizing a key message: obesity is a manifestation of a broader metabolic problem. From her early career in women's health to her transition into obesity medicine, Courtney offered her account from the frontlines of treating metabolic dysfunction, noting up to 97% of Americans experience some form of metabolic disorder in their lifetimes. GLP-1 agonists can create the mental space for patients to implement meaningful lifestyle changes. Yet, our conversation should not just be about losing weight. Tackling insulin resistance, inflammation, poor diet and sleep are all equally important. Investing in building a holistic foundation of health is still essential for patients to truly thrive moving forward. Read the full summary of our event in the link in the comments below. #ObesityMedicine #MetabolicHealth #GLP1 #Pharmaceuticals

We all talk about weight loss + physical health benefits of GLP/GIPs, but so important to broaden the aperture: how is quality of life impacted when using GLP1s for obesity? Here https://lnkd.in/eWg_Zx3b my colleagues Robert Hsu Anne-Kathrin Eiselt, Ph.D. and I propose further research needed to better understand QOL: 1+2) impact of pt characteristics and 'dose response' of weight loss 3) changes w attitudes/expectations 4) interactions w providers and 5) realities of coverage/supply chain challenges. #GLPs #obesitycare #qualityoflife

Obesity is complex, with physical, emotional, and social challenges impacting an individual's quality of life (QoL) as well as treatment success. For holistic obesity care and sustainable health changes, we must better understand how different treatments (like GLP1s) contribute to overall well-being, mental health, and daily life. ? Here, we suggest 5 components that influence the QoL of obese patients on GLP1 medication that should be included in future RCTs.?Better understanding the nuanced impact of treatments allows us to better support the health journey of patients through effective patient-centered solutions.?

Understanding the underlying pathophysiology of obesity and diabetes, including the development of insulin resistance, is critical for diabesity treatment. Read our new blog to better understand how ideal therapeutic targets for diabesity address shared underlying mechanisms of both conditions. https://ow.ly/p8Ge50R4NLx

According to a 2023 report from the World Obesity Atlas (WOA), roughly half of the global population—or approximately 4 billion people—will be considered clinically obese by 2035. Further research into the underlying mechanisms regulating hyperglycemia and obesity is necessary if we are to successfully address this escalating global health concern. To further explore the mechanisms of metabolic diseases, we offer several models, including B-ob/ob mice(https://lnkd.in/edPaYb4R), humanized B-hGLP1R Mice(https://lnkd.in/eTcsmYay) and humanized B-hGCGR mice(https://lnkd.in/eMtmRHEN). #metabolicdisease?#Obesity?#glp1forweightloss?#gpcr?#GLP1?#PCSK9?#gcgr #glp1weightloss?#MouseModel?#pharmacology

Thrilled to announce the publication of our recent article, Innovative Glucagon-Based Therapies for Obesity, in the esteemed Journal of the Endocrine Society, of which I am a proud member! Here is the overview of the article. ? Obesity is a global health challenge with limited success in achieving sustainable weight loss through traditional interventions. ? Glucagon-based therapies have emerged as potential treatments due to their effects on metabolism, appetite regulation, and energy expenditure. ? Single and dual agonist therapies targeting various receptors show promise in managing obesity and its comorbidities. ? Triple-agonist therapies targeting GLP-1R, GIPR, and GcgR demonstrate augmented metabolic benefits. ? Ongoing research, including phase III trials, aims to further validate the efficacy and safety of these innovative treatment modalities. https://lnkd.in/eWAhWGRm

Exciting findings reveal Tirzepatide's future potential. New research shows a significant reduction in Diabetic Peripheral Neuropathy (DPN) risk over 2 years compared to insulin and other therapies, highlighting dual benefits in diabetes and obesity management with potential neuroprotective effects. This suggests broader implications beyond traditional diabetes management. Link: tinyurl.com/5xx9d3fr #DiabetesResearch #Neuroprotection #Tirzepatide"